General Information
Revision date
2016-04-20
Product name
OMEPRAZOLE DELAYED-
Substance name
Omeprazole Delayed-Release Capsules
Chemical name
substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5- dimethyl-2- pyridinyl) methyl] sulfinyl]1H-benzimidazole
CAS No.
73590-58-6
1.2.1 Relevant identified uses
the H, /K, ATPase enzyme system at the secretary surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterised as a gastric-pump inhibitor
Emergency telephone
(201) 684-8000
Icons in SDS
Company Information
company name
Glenmark Pharmaceuticals Inc.
Section 2
EU Classification
Regulation GHS Chemwatch Hazard Ratings MinMax Flammability 1 Toxicity 1 Body Contact 2 Reactivity 1 Chronic 1 0 = Minimum 1 = Low 2 = Moderate 3 = High 4 = Extreme
2.2 Label elements
Relevant risk statements are found in section 2
Hazard statements
R36/37/38 Irritating to eyes, respiratory system and skin. R43 May cause SENSITISATION by skin contact. Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic R52/53 environment.
Precautionary statements
S02 Keep out of reach of children. S22 Do not breathe dust. S24 Avoid contact with skin. In case of contact with eyes, rinse with plenty of water and contact Doctor or Poisons S26 Information Centre. S35 This material and its container must be disposed of in a safe way. S37 Wear suitable gloves. S39 Wear eye/face protection. To clean the floor and all objects contaminated by this material, use water and S40 detergent. S46 If swallowed, seek medical advice immediately and show this container or label. Dispose of this material and its container at hazardous or special waste collection S56 point. S64 If swallowed, rinse mouth with water (only if the person is conscious).
2.3 Other hazards
Ingestion may produce health damage*. Cumulative effects may result following exposure*. Limited evidence of a carcinogenic effect*. Exposure may produce irreversible effects*.
